PleoPharma
Prescription Drugs
$70.9Mtotal raised · 6 rounds on record
$36Mlatest round · Series B · Oct 2025 · 12 mo ago
1backers · Florida Opportunity Fund
50+team · employees, estimated range
Overview
PleoPharma pharmaceutical company homepage, management team, product offering, contact us.
Funding and backers
Total raised
$70.9M
6 rounds on record
Latest round
$36M
Series B · Oct 2025 · 12 mo ago
Team
51-200
employees, estimated range
Backers
1
Florida Opportunity Fund
The money's age
Due for its next round
12 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 10
Board appointment Tommy Thompson, Director · SEC Form D
Jul 28
Took on debt financing $5.5M · SEC Form D
Oct 21, 2025
Raised a round Series B $36M
Jun 23, 2025
Raised a round Venture round $6.2M · SEC Form D
Jun 30, 2023
Raised a round Series A $17.5M · led by DynaGrow Capital
May 2, 2022
Raised a round Venture round $11.1M · SEC Form D
Jan 27, 2020
Raised a round Venture round $130k · SEC Form D
2020
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Debt Financing | Jul 2026 | $5.5M | — | SEC Form D |
| Series B | Oct 2025 | $36M | — | pleopharma.com |
| Venture round | Jun 2025 | $6.2M | — | SEC Form D |
| Series A | Jun 2023 | $17.5M | DynaGrow Capital lead, MintPharma Capital and lead | pleopharma.com |
| Venture round | May 2022 | $11.1M | — | SEC Form D |
| Venture round | Jan 2020 | $130k | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Pleopharma L.L.C. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Jay ConstantineExecutive Officer, DirectorSEC Form D
Robert FinizioExecutive Officer, DirectorSEC Form D
Ginger ConstantineExecutive Officer, DirectorSEC Form D
Thomas PocheExecutive OfficerSEC Form D
Daniel CartwritghtExecutive OfficerSEC Form D
Daniel CartwrightExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Together for Health. Noucor Completes Acquisition of HELM Pharmaceutical.
Validproof assists pharmaceutical companies meet their traceability obligation and ensure that their medicine makes it into the right hands.
Home Our Vision Our Approach Leadership Team News Contact Us Book Appointment Now Executive Team Dr. Mohammad Ali Amini CEO Chief Executive…
Lisata is a clinical-stage pharmaceutical company dedicated to improving lives through the discovery, development, and commercialization of…
Azurity Pharmaceuticals is a privately held specialty pharmaceutical company that develops and markets medicines for patients underserved…
上海拓臻生物科技有限公司（Terns Pharmaceuticals）致力于创新药物研发，依托多学科平台推进科研项目转化。网站提供公司介绍、研发进展、新闻动态及人才招聘等信息。.
Financials
Total raised
$76.4M
Latest round
Debt Financing
Funding rounds
6
People
Jay Constantine
Executive Officer, Director
Robert Finizio
Executive Officer, Director
Ginger Constantine
Executive Officer, Director
Thomas Poche
Executive Officer
Daniel Cartwritght
Executive Officer
Daniel Cartwright
Executive Officer
Poche Thomas
Executive Officer
Paul Bisaro
Director
Sarah Hassan
Director
Timothy McInerney
Director
Bisaro Paul
Director
Thompson Tommy
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Florida Opportunity FundVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
PleoPharma Wins $6.5 Million NIDA Grant To Advance Phase 3 Cannabis Withdrawal Treatment
PleoPharma has received a $6.5 million, three-year grant from the National Institute on Drug Abuse to support its pivotal Phase 3 clinical program evaluating PP-01 as an investigational treatment for cannabis withdrawal symptoms in adults with cannabis us
Read more
Report
PleoPharma Awarded $6.5 Million NIDA Grant to Support Phase 3 Trial of PP-01 for Cannabis Withdrawal in Patients with Cannabis Use Disorder
PleoPharma, Inc., a clinical-stage development company focused on cannabis-related health issues, today announced the award of a $6.5 million, three-year grant from the National Institute on Drug Abuse (NIDA)
Read more
Report
PleoPharma Awarded $6.5 Million NIDA Grant to Support Phase 3 Trial of PP-01 for Cannabis Withdrawal in Patients with Cannabis Use Disorder
Read more
Report
PleoPharma, Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Trial of PP-01 (CAN-004) for Mitigation of Cannabis Withdrawal Symptoms in Patients with Cannabis Use Disorder
/PRNewswire/ -- PleoPharma, Inc., a clinical-stage development company focused on cannabis-related health issues, today announced that the first patient has...
Read more
Report
PleoPharma, Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Trial of PP-01 (CAN-004) for Mitigation of Cannabis Withdrawal Symptoms in Patients with Cannabis Use Disorder
Phase 3 trial initiation advances PP-01, an investigational, once-daily therapy for cannabis withdrawal symptoms in patients with cannabis use disorder
Read more
Report
PLEOPHARMA TO PRESENT NEWDATA ON CANNABIS WITHDRAWAL In PATIENTS WITH CANNABIS USE DISORDER AND PHASE 2 PP-01 RESULTS AT THE COLLEGE ON PROBLEMS OF DRUG DEPENDENCE 88TH ANNUAL SCIENTIFIC MEETING
PleoPharma, a clinical-stage clinical development company focused on cannabis-related health issues, announced today that it will present two posters at the College on Problems of Drug Dependence (CPDD) 88th Annual Scientific Meeting, taking place June 13
Read more
Report
PLEOPHARMA TO PRESENT NEWDATA ON CANNABIS WITHDRAWAL In PATIENTS WITH CANNABIS USE DISORDER AND PHASE 2 PP-01 RESULTS AT THE COLLEGE ON PROBLEMS OF DRUG DEPENDENCE 88TH ANNUAL SCIENTIFIC MEETING
/PRNewswire/ -- PleoPharma, a clinical-stage clinical development company focused on cannabis-related health issues, announced today that it will present two...
Read more
Report
PLEOPHARMA TO PRESENT NEW DATA ON CANNABIS WITHDRAWAL IN PATIENTS WITH CANNABIS USE DISORDER AND PHASE 2 PP-01 RESULTS AT THE COLLEGE ON PROBLEMS OF DRUG DEPENDENCE 88TH ANNUAL SCIENTIFIC MEETING
Presentations will highlight the patient experience of cannabis withdrawal/cannabis use disorder and Phase 2 CAN-002 data for investigational PP-01 in adults with cannabis use disorder PHOENIXVILLE, Pa., June 15, 2026 /PRNewswire/ -- PleoPharma, a clinica
Read more
Report
PLEOPHARMA, INC. to Present at the Centri Capital Conference in New York
PleoPharma, Inc., a privately held company focused on finding treatments for cannabis related health issues, announced today that management will present at the Centri Capital Conference in New York City on April 14, 2026 at 8:30 a.m. Eastern Time (ET).
Read more
Report
PLEOPHARMA, INC. to Present at the Centri Capital Conference in New York
PleoPharma, Inc., a privately held company focused on finding treatments for cannabis related health issues, announced today that management will present at the Centri Capital Conference in New York City on April 14, 2026 at 8:30 a.m. Eastern Time (ET).
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Phoenixville
United States
HQ
50-200 est. staff
518 Kimberton Road, Phoenixville, PA, 19460, US